ClinicalTrials.gg
CompletedNCT05249348Updated Nov 13, 2024

Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers

A Phase 1 interventional study of PC14586 in Healthy Volunteers, sponsored by PMV Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-13.

Sponsored by PMV Pharmaceuticals, Inc · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a 2-part Phase 1 cross-over study to assess the effects of food on the pharmacokinetics of PC14586 in healthy volunteers. The pharmacokinetics of PC14586 at a clinically relevant dose in Japanese participants will also be studied.

Read the detailed description

PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the p53 Y220C mutation. This Phase 1 trial will be conducted in 2 parts (Part 1 - pilot and Part 2 - pivotal) to assess the pharmacokinetics of PC14586 in healthy volunteers including Japanese participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Y220C
  • PC14586
  • PMV Pharma
  • PMV
  • food effect
  • Pharmacokinetics
  • Japanese
03

In context

Lead sponsor

PMV Pharmaceuticals, Inc is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy, non-smoking male and female Caucasian/ non-Asian or Japanese human volunteers
  • 18 to 55 years of age
  • Able to swallow tablets.

Inclusion criteria for Japanese participants only:

  • Japanese and born in Japan (1st generation)
  • The parents and grandparents of the participant are ethnically Japanese and born in Japan
  • Has undergone no significant change in lifestyle since leaving Japan
  • Has lived \< 10 years outside of Japan

Exclusion Criteria:

  • medical history as determined by the PI.
  • Any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs.
  • A p53 Y220C mutation.
  • Blood pressure >140 mm systolic or >90 diastolic.
  • Smoked or used other nicotine-containing products during the previous 3 months.
  • History of alcohol and/or illicit drug abuse within the previous 5 years.
  • surface antigen (HBsAg), antibody or (HIV).
  • Positive blood test for ethanol.
  • Positive urine drug test.
  • Pregnancy or breastfeeding.
  • Unwilling to avoid use of alcohol or alcohol-containing foods, medications or beverages, within 48 hours prior to admission until discharge from the clinical site.
  • Has donated blood within 2 months prior to admission.
  • Has used over-the-counter (OTC) medications (including vitamins), prescription medications or herbal remedies from 14 days prior to admission.
  • Has used an drug within 30 days prior to Screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Part 1 Sequence A

    Period 1 will be fed, then washout, then Period 2 will be fasted.

    Drug: PC14586

  • Experimental
    Part 1 Sequence B

    Period 1 will be fasted, then washout, then Period 2 will be fed.

    Drug: PC14586

  • Experimental
    Part 2 Sequence C

    Period 1 will be fed, then washout, then Period 2 will be fasted. A different dose of PC14586 will be tested.

    Drug: PC14586

  • Experimental
    Part 2 Sequence D

    Period 1 will be fasted, then washout, then Period 2 will be fed. A different dose of PC14586 will be tested.

    Drug: PC14586

  • Experimental
    Part 2 Japanese Cohort

    6 Japanese participants will be administered a single dose of PC14586.

    Drug: PC14586

Interventions

  • An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).

06

What researchers measure

Primary outcomes

  1. Part 1: Effect of a high-fat meal on AUClast

    Time frame: 2 months

  2. Part 1: Effect of a high-fat meal on AUC0-inf

    Time frame: 2 months

  3. Part 1: Effect of a high-fat meal on the Tmax

    Time frame: 2 months

  4. Part 1: Effect of a high-fat meal on the Cmax

    Time frame: 2 months

  5. Part 2: Effect of a high-fat meal on the AUC0-last

    Time frame: 7 months

  6. Part 2: Effect of a high-fat meal on the AUC0-inf

    Time frame: 7 months

  7. Part 2: Effect of a high-fat meal on the Tmax

    Time frame: 7 months

  8. Part 2: Effect of a high-fat meal on the Cmax

    Time frame: 7 months

Secondary outcomes

  1. Part 1: Treatment emergent adverse events (TEAE)

    Time frame: 5 months

  2. Part 1: Clinically relevant changes in: physical examinations, vital signs, clinical laboratory tests, 12-lead triplicate electrocardiogram (ECG)

    Time frame: 5 months

  3. Part 2: AUC0-last of PC14586

    Time frame: 6 months

  4. Part 2: AUC0-inf of PC14586

    Time frame: 6 months

  5. Part 2: Cmax of PC14586

    Time frame: 6 months

  6. Part 2: Tmax of PC14586

    Time frame: 6 months

  7. Part 2: The apparent clearance (CL/F) of PC14586

    Time frame: 6 months

  8. Part 2: Volume of distribution (Vz/F) of PC14586

    Time frame: 6 months

  9. Half-life of PC14586

    Time frame: 6 months

  10. Part 2: Incidence of Treatment emergent adverse events (TEAE)

    Time frame: 10 months

07

Study locations

1 site
  • Parexel Early Phase Clinical Unit - Los Angeles
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jun 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2022
First posted
Feb 21, 2022
StartActual
Dec 20, 2021
Primary completionActual
Jun 9, 2022
CompletionActual
Jun 9, 2022
Last update
Nov 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05249348
Lead sponsor
PMV Pharmaceuticals, Inc
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Dec 20, 2021
Primary completion
Jun 9, 2022
Completion
Jun 9, 2022
Last update
Nov 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezatapopt

Start the discussion